Health-ITInnovationNews

Calicut Centre for Surgery partners with NIRAMAI Health Analytix

To provide contact-less breast cancer screening 

Dr Ambadi’s Calicut Centre for Surgery (CCS) located at Metromed Hospital has partnered with NIRAMAI Health Analytix, an AI-based breast cancer screening company, to offer contactless, privacy-sensitive, breast cancer screening services to customers.

Niramai’s innovative solution called ‘Thermalytix’, is an automated breast health screening and diagnostic tool, which combines thermal imaging with artificial intelligence.

With this collaboration, women can also avail of home-screening services which will bring this novel non-touch breast cancer screening solution to the door-step of homes reducing the need to go to a hospital during the pandemic. Only female technicians will provide this service following all covid safety precautions and women can avail of this service with a prior appointment. The test will be conducted in complete privacy without any physical contact. NIRAMAI Thermalytix test is appropriate for women of 18 years and above. It is privacy-aware, non-invasive, radiation-free, and can detect the minutest of lumps or other abnormalities.

Dr Geetha Manjunath, Founder & CEO, Niramai, added, “We are excited to partner with Dr. Ambadi’s Calicut Centre for Surgery to take our clinically proven Thermalytix screening service to many more women in India and help save lives. We are also conducting many free programmes to raise awareness amongst women about early detection of breast cancer and educating the masses on the importance of frequent checks.”

Dr  Abdurahman Ambadi, Chairman & Chief Laparoscopic Surgeon of CCS, said, “We are committed to offering the best surgical healthcare services to our customers. Collaborating with an innovative company like Niramai to offer early-stage breast screening will surely be beneficial to our patients.”

 

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close